Disclosed is optically active (-)-O-exo/C-exo-tryicyclo[5.2.1.02.6]-dec-9-yl-xanthic acid or pharmaceutically acceptable salts thereof. Also disclosed are methods of making the said optical isomer. The use of the optical isomer for treating cancer, viral infections, autoimmune diseases, inflammatory diseases and neurodegenerative diseases is also disclosed.